What they were paid
Verve Therapeutics Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2024 | $52,500 | $0 | $468,999 | $0 | $521,499 |
| FY2022 | $16,862 | — | $577,437 | — | $594,299 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Verve Therapeutics, Inc. DEF 14A filed April 25, 2025, accession 0000950170-25-058325, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2024Verve Therapeutics pays directors a $45,000 cash retainer and $468,999 in Options.
Committees
FY2024 · as the proxy prints themAudit
The rest of the Verve Therapeutics board
FY2024 · as the company reported each| Director | Role | FY2024 total |
|---|---|---|
| Alexander Cumbo | Independent Director | $521,499 |
| Burt Adelman, M.D | Chair of the Board | $568,999 |
| Jodie Morrison | Independent Director | $964,970 |
| Krishna Yeshwant, M.D | Independent Director | $522,667 |
| Michael MacLean | Independent Director | $533,999 |
| Ourania Tatsis, Ph.D | Director | — |
| Sekar Kathiresan, M.D | Director | $0 |
| Sheila Mikhail, J.D | Independent Director | $526,499 |
The full Verve Therapeutics compensation record
free company briefThis page is one director within Verve Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat